EP4376822A4 - Behandlung von krebs mit kombinationen aus parp-inhibitor und acylfulvenen - Google Patents
Behandlung von krebs mit kombinationen aus parp-inhibitor und acylfulvenenInfo
- Publication number
- EP4376822A4 EP4376822A4 EP22850545.9A EP22850545A EP4376822A4 EP 4376822 A4 EP4376822 A4 EP 4376822A4 EP 22850545 A EP22850545 A EP 22850545A EP 4376822 A4 EP4376822 A4 EP 4376822A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- acylfulvenes
- cancer
- combinations
- treatment
- parp inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227260P | 2021-07-29 | 2021-07-29 | |
| US202263365995P | 2022-06-07 | 2022-06-07 | |
| PCT/US2022/074314 WO2023010119A1 (en) | 2021-07-29 | 2022-07-29 | Treating cancers with combinations of parp inhibitor and acylfulvenes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4376822A1 EP4376822A1 (de) | 2024-06-05 |
| EP4376822A4 true EP4376822A4 (de) | 2025-09-17 |
Family
ID=85087343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22850545.9A Pending EP4376822A4 (de) | 2021-07-29 | 2022-07-29 | Behandlung von krebs mit kombinationen aus parp-inhibitor und acylfulvenen |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4376822A4 (de) |
| JP (1) | JP2024528725A (de) |
| CA (1) | CA3227306A1 (de) |
| MX (1) | MX2024001314A (de) |
| WO (1) | WO2023010119A1 (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4554683A2 (de) * | 2022-07-15 | 2025-05-21 | Lantern Pharma Inc. | Verfahren zur behandlung von brustkrebs und parp-resistentem brustkrebs |
| AU2024233068A1 (en) * | 2023-03-09 | 2025-10-23 | Lantern Pharma Inc. | Method for treating renal cell carcinoma or cancer |
| AU2024327731A1 (en) * | 2023-08-23 | 2026-03-05 | Lantern Pharma Inc. | Treating liver cancers with hydroxyureamethyl acylfulvene |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4989648B2 (ja) * | 2005-08-03 | 2012-08-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗癌剤として有用なイルジン類似体 |
| FI3386546T3 (fi) * | 2015-12-07 | 2024-12-05 | General Oncology Inc | Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla |
| CA3116552A1 (en) * | 2018-10-14 | 2020-04-23 | Lantern Pharma Inc. | Methods for the treatment of solid tumor cancers using illudins and biomarkers |
-
2022
- 2022-07-29 MX MX2024001314A patent/MX2024001314A/es unknown
- 2022-07-29 JP JP2024505026A patent/JP2024528725A/ja active Pending
- 2022-07-29 WO PCT/US2022/074314 patent/WO2023010119A1/en not_active Ceased
- 2022-07-29 CA CA3227306A patent/CA3227306A1/en active Pending
- 2022-07-29 EP EP22850545.9A patent/EP4376822A4/de active Pending
Non-Patent Citations (3)
| Title |
|---|
| KULKARNI A ET AL: "LP184, a novel alkylating agent, is efficacious in prostate cancer models with DNA damage repair defects", CANCER RESEARCH, vol. 81, no. 13_Suppl, 1 July 2021 (2021-07-01), XP093300530, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2021-1249 * |
| See also references of WO2023010119A1 * |
| UMESH KATHAD ET AL: "A machine learning-based gene signature of response to the novel alkylating agent LP-184 distinguishes its potential tumor indications", BMC BIOINFORMATICS, BIOMED CENTRAL LTD, LONDON, UK, vol. 22, no. 1, 2 March 2021 (2021-03-02), pages 1 - 23, XP021287233, DOI: 10.1186/S12859-021-04040-8 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024001314A (es) | 2024-04-30 |
| CA3227306A1 (en) | 2023-02-02 |
| EP4376822A1 (de) | 2024-06-05 |
| JP2024528725A (ja) | 2024-07-30 |
| WO2023010119A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4326720A4 (de) | Parp1-inhibitoren und verwendungen davon | |
| EP3600382A4 (de) | Behandlung von krebs mit cas-endonuklease-komplexen | |
| EP3585817A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| EP4412716A4 (de) | Kombinationen aus kras-g12d-inhibitoren und pi3ka-inhibitoren und zugehörige behandlungsverfahren | |
| EP3612222A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| EP4125846A4 (de) | Pyrazolylpropanamidverbindungen und verwendungen davon zur behandlung von prostatakrebs | |
| EP4355749A4 (de) | Tricyclische parp1-inhibitoren und verwendungen davon | |
| EP3592346A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| EP4376821A4 (de) | Behandlung von krebs mit kombinationen aus spironolacton und acylfulvenen | |
| EP3528834A4 (de) | Behandlung von krebs mit einer kombination aus einem pd-1-antagonisten und einem il-27-inhibitor | |
| EP3873613A4 (de) | 5-halouracil-modifizierte mikrornas und deren verwendung in der behandlung von krebs | |
| EP4412720A4 (de) | Kombinationen aus kras-g12d-inhibitoren und irinotecan und zugehörige behandlungsverfahren | |
| EP4232052A4 (de) | Kombination aus radioimmuntherapie und cd47-blockade bei der behandlung von krebs | |
| IL283899A (en) | Combinations of a hdm2-p53 interaction inhibitor and a bcl2 inhibitor and their use for treating cancer | |
| EP3820492A4 (de) | Apmv und ihre verwendungen zur behandlung von krebs | |
| EP3877422A4 (de) | Therapeutische dosierpläne zur behandlung von krebs mit eribulin und selektiven cdk4/6-inhibitorkombinationen | |
| EP4203979C0 (de) | Behandlung von krebs und autoimmun- und entzündungskrankheiten | |
| EP3600329A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| EP4412613A4 (de) | Verfahren zur behandlung von krebs und tumoren | |
| EP3532289A4 (de) | Polyoxometallatkomplexe und verwendungen in der behandlung von krebs | |
| EP3585398A4 (de) | Zusammensetzungen und verfahren zur behandlung von krebs | |
| EP3570837A4 (de) | Zusammensetzungen und verfahren zur behandlung von androgenunabhängigem krebs | |
| EP3826623A4 (de) | Zusammensetzungen und verfahren zur behandlung von mit pcsk9-expression charakterisiertem krebs | |
| EP4301356A4 (de) | Behandlung von brustkrebs mit amcenestratant und palbociclib | |
| EP4247406A4 (de) | Behandlung von enpp1-mangel und abcc6-mangel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240228 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20250819 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/122 20060101AFI20250812BHEP Ipc: C07C 35/22 20060101ALI20250812BHEP Ipc: C07C 49/727 20060101ALI20250812BHEP Ipc: A61P 35/00 20060101ALI20250812BHEP Ipc: A61K 31/166 20060101ALI20250812BHEP Ipc: A61K 31/4184 20060101ALI20250812BHEP Ipc: A61K 31/454 20060101ALI20250812BHEP Ipc: A61K 31/5025 20060101ALI20250812BHEP Ipc: A61K 31/55 20060101ALI20250812BHEP Ipc: A61K 31/502 20060101ALI20250812BHEP Ipc: A61K 9/00 20060101ALI20250812BHEP Ipc: A61K 31/337 20060101ALI20250812BHEP Ipc: A61K 33/243 20190101ALI20250812BHEP |